Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. - Test2 - elhamkhani - TriplyDB

Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine.

Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine.

http://www.wikidata.org/entity/Q34566171

about

Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates Animal models for Ebola and Marburg virus infections Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates Current ebola vaccines Durability of a vesicular stomatitis virus-based marburg virus vaccine in nonhuman primates Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses Filoviruses: One of These Things is (not) Like the Other Mouse models for filovirus infections Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)Neglected filoviruses Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species Ebola and Marburg virus vaccines.Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.Vesicular stomatitis virus-based vaccines protect nonhuman primates against Bundibugyo ebolavirus Development and characterization of a mouse model for Marburg hemorrhagic fever Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus Refined methods for propagating vesicular stomatitis virus vectors that are defective for G protein expression.Different potential of C-type lectin-mediated entry between Marburg virus strains Recombinant vesicular stomatitis virus vector mediates postexposure protection against Sudan Ebola hemorrhagic fever in nonhuman primates Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice.Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses.Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial Sequence variability in viral genome non-coding regions likely contribute to observed differences in viral replication amongst MARV strains Antibody-dependent enhancement of Marburg virus infection Single immunization with a monovalent vesicular stomatitis virus-based vaccine protects nonhuman primates against heterologous challenge with Bundibugyo ebolavirus.Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection Clinical aspects of Marburg hemorrhagic fever Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections Filovirus vaccines.Evaluation of perceived threat differences posed by filovirus variants.Vesicular Stomatitis Virus-Based Vaccines for Prophylaxis and Treatment of Filovirus Infections.A Comparison of the Pathogenesis of Marburg Virus Disease in Humans and Nonhuman Primates and Evaluation of the Suitability of These Animal Models for Predicting Clinical Efficacy under the 'Animal Rule'.Marburg virus infection in nonhuman primates: Therapeutic treatment by lipid-encapsulated siRNA.Comparison of the Pathogenesis of the Angola and Ravn Strains of Marburg Virus in the Outbred Guinea Pig Model.Temporal Characterization of Marburg Virus Angola Infection following Aerosol Challenge in Rhesus Macaques.Prospects for immunisation against Marburg and Ebola viruses.Progress in filovirus vaccine development: evaluating the potential for clinical use.Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges

P2860

Q21090120-69BD42E0-2690-4D98-86DF-2ADDC4722A26 Q21131118-07107669-4F74-4FC2-A3A6-8D6931B24606 Q21131585-F2AD5077-0BD1-4A8D-852C-2B93629BEC44 Q21534720-9586E888-121A-4C9D-B974-A6494C9D28A0 Q21559476-E707BDFF-2775-4D46-9D84-0EFCE4E83F3C Q21562420-679266F0-99AB-4CC9-BBA7-E2BCE978F463 Q26783063-D5353054-CBE6-4910-9019-7EE7D7F2CB56 Q27011569-23734927-B13B-42E1-A692-8211A892B2D0 Q28051937-DB7161B1-08BB-44AF-9992-561E20506E92 Q28383265-CC1CCFF6-4F82-42C1-BA52-6862BB1A6181 Q28485505-6C24162D-3426-4367-B222-4B9830891431 Q30234637-3C277357-ED03-4B9E-913F-78C4079DAB18 Q30361939-8548E2C8-98FA-4219-BE31-BABAD7B8302B Q30724121-E47D77F8-E00F-4E22-9A15-901650480A05 Q33384111-AE96E98A-5D7D-42F2-B402-F29649E07CD7 Q33417197-CFFACE3B-B04A-4B44-815E-595B53D6F66E Q33721746-0000FCAE-6BCE-4D31-A4CF-62CDE49F7052 Q33826885-FCB268CA-12B2-42C7-AFB2-33EBF2C4A00B Q34589949-54EC7BF7-5F88-4D2E-B6FD-F06CA942EB6A Q34598925-075BED2E-CD5B-452C-AA60-F420CB75B386 Q34606818-BF3B7335-7543-4F6B-B6E7-CC2A7265F435 Q34761889-FA5B9902-C954-4FD8-AFD3-669D13149177 Q34774783-90E4A8DD-B445-48AF-B4C9-D693900E4A84 Q35055198-EF291094-E88F-4B54-AF1F-8BF81598DEB0 Q35077488-7570A562-8DC3-4748-8459-1AB1B9A23368 Q35299989-D51AC622-DDED-4BA5-BD76-A61A14E7F489 Q35300062-9C8BED7D-3871-4883-80A6-AB7686962DB1 Q35300104-3390B9F5-F257-460E-819A-565715031EA6 Q35446144-4EAE581E-E0A9-4681-87C9-FE7A5330BD70 Q35557184-3E9BC744-A184-4FC2-BB5E-59780A41976E Q35558539-78CC9955-69C4-46EB-A6FA-51375BD0B92F Q35601783-2EF79E95-3AFC-4230-B13B-6554223795D9 Q35693152-AEB79E6D-1848-40EB-83ED-EA16B0749CD7 Q35798489-01E232F9-F731-489B-BA9B-AA355E59E4C9 Q35852525-77C726D9-BFBD-473F-9C23-98DB69BBED89 Q36043232-EB6DF1B5-56E2-4000-AE72-B4265E4F7146 Q36080908-2BD2549A-5807-4C29-AE8C-E3600A581AE2 Q36088118-0607427A-9E44-420C-A18F-2150051BE60F Q36100545-1271F212-9A67-4044-9140-A8423D9E5295 Q36255716-60BCC50F-87B9-4888-93C4-4D747F058D6B

P2860

Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine.

http://www.wikidata.org/entity/Q34566171

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

Cross-protection against Marbu ...... ttenuated recombinant vaccine.

@ast

Cross-protection against Marbu ...... ttenuated recombinant vaccine.

@en

Cross-protection against Marbu ...... ttenuated recombinant vaccine.

@nl

type

label

Cross-protection against Marbu ...... ttenuated recombinant vaccine.

@ast

Cross-protection against Marbu ...... ttenuated recombinant vaccine.

@en

Cross-protection against Marbu ...... ttenuated recombinant vaccine.

@nl

prefLabel

Cross-protection against Marbu ...... ttenuated recombinant vaccine.

@ast

Cross-protection against Marbu ...... ttenuated recombinant vaccine.

@en

Cross-protection against Marbu ...... ttenuated recombinant vaccine.

@nl

P1433

Q34566171-E1C47066-C806-45ED-88E9-0D3720D2384E

P1476

Q34566171-AA64F5BB-5EE6-44C1-BAC2-217FC94EFC1E

P2093

Q34566171-B620D503-AC22-42FB-80E7-488D58B6193A

Q34566171-C2C9269F-6B96-45A1-AA7E-A0E67E3FD568

Q34566171-F767FD56-58E1-4988-B9B5-B10814910877

P2860

Q34566171-000634B3-1C8E-41AE-A755-A7CF44D18D9D

Q34566171-1BA40716-A4E2-4D73-8803-95CAAECE1BDE

Q34566171-3843970F-F9BC-428C-A714-B72C96B6A849

Q34566171-3C538085-3F73-4C9C-B719-3A0FE5A6E142

Q34566171-3CD23007-6000-4582-8F9C-11FBBA60A39E

Q34566171-63BDA867-7026-440F-BF2A-4A5F3A8EEB51

Q34566171-661EA8EF-FCC3-4B41-BB6A-155F8885E344

Q34566171-6E804099-19FD-42EE-9E58-7CC86A987F0A

Q34566171-837A0AB2-3FAC-4531-9388-9029CC7F28AF

Q34566171-8FA0E68E-1A3C-4F8D-8F5F-968CD0EE62D9

P304

Q34566171-8C721BF8-6692-4A61-B557-C20DF9902582

P31

Q34566171-13EBB456-8392-4CA3-B011-DB3633A29F5A

P356

Q34566171-FDB613C2-F65C-4A66-B56B-333CF88A2FDE

P407

Q34566171-1E99C74C-10EC-4DC8-9974-9DB8BF41905F

P433

Q34566171-E6C44537-5786-480C-8BF6-8CAEC8687C8D

P478

Q34566171-70CC0015-9C3D-437E-9F3F-3144D7C713D8

P50

Q34566171-26650F47-1FDA-435D-A8FD-6F1AC2706CEA

Q34566171-2DF9DA99-25B2-44C7-BBD0-CEBAB12A6D42

Q34566171-6B45F793-A7AD-489C-93F4-B5FFDC85B582

Q34566171-78F04B23-8480-44D2-9FCD-A27655D05DF9

Q34566171-C45B3978-802E-4B3F-9EB0-8D4D83B580DC

Q34566171-EF8F1226-DEB3-42DE-B27D-D6DF12572A97

Q34566171-F52927BE-FD33-4A12-B977-F1760B623B78

P577

Q34566171-F397CC8C-2EB2-4FD3-9DD6-4A98093BDA9E

P5875

Q34566171-67BC3AB6-33F2-4F70-AACD-E975C025FA35

P698

Q34566171-054E4F3B-908A-4DD1-9DCA-573ED53C80AD

P921

Q34566171-97B72BF7-ABEE-4C03-BD65-77FFC52EBDA2

Q34566171-FFF0DA61-3232-4F11-A41B-6011537EC411

P932

Q34566171-4FF56019-456D-40DE-831E-6208F5442265

P356

P1433

Journal of Virology

P1476

Cross-protection against Marbu ...... ttenuated recombinant vaccine.

@en

P2093

Elizabeth A Fritz

http://www.w3.org/2001/XMLSchema#string

Joan B Geisbert

http://www.w3.org/2001/XMLSchema#string

Steven M Jones

http://www.w3.org/2001/XMLSchema#string

P2860

Development of a new vaccine for the prevention of Lassa fever.

Development of a preventive vaccine for Ebola virus infection in primates

Immune responses to adenovirus and adeno-associated virus in humans.

Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses.

Marburg-virus disease in Kenya.

Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya.

A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector.

Hemorrhagic fever viruses as biological weapons: medical and public health management.

Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.

Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses.

P304

9659-9666

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.00959-06

http://www.w3.org/2001/XMLSchema#string

P407

P433

19

http://www.w3.org/2001/XMLSchema#string

P478

80

http://www.w3.org/2001/XMLSchema#string

P50

Thomas W Geisbert

Friederike Feldmann

Kathleen M Daddario-DiCaprio

P577

2006-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6816949

http://www.w3.org/2001/XMLSchema#string

P698

16973570

http://www.w3.org/2001/XMLSchema#string

P921

attenuated vaccine

P932

1617222

http://www.w3.org/2001/XMLSchema#string